Journal article
US Clinical Practice Patterns of Intravesical Chemotherapy for BCG-Unresponsive and BCG-Exposed Non-muscle Invasive Bladder Cancer
Urology Practice, Vol.11(1), pp.97-107
01/2024
DOI: 10.1097/UPJ.0000000000000481
PMID: 37903746
Abstract
The goal of this survey was to evaluate the treatment and practice pattern of patients with high-grade papillary Ta, T1 nonmuscle-invasive bladder cancer (NMIBC), and carcinoma in situ (CIS) in bacillus Calmette-Guérin (BCG)–unresponsive (with adequate BCG exposure=adequate BCG) and those with less than adequate BCG exposure (BCG-exposed).
Methods:
An internet-based survey with a target duration of 5 minutes was sent to US urologists who manage patients with NMIBC. Respondents were recruited from the Sesen Bio target list based upon BCG utilization.
Results:
In 2022, 100 urologists who manage patients with papillary tumors and 159 urologists who manage patients with CIS tumors filled out the survey. Most (78%) were community-based urologists. Study respondents managed an average of 33 (range: 6-158) CIS patients and 44 (range: 10-200) high-grade patients with papillary disease (without CIS) over the past 6 months. Approximately 70% of physicians identified either gemcitabine (∼40%) or mitomycin C (∼30%) as the most often used intravesical chemotherapies for BCG unresponsive and BCG exposed groups. Most physicians reported the use of gemcitabine 2 g or mitomycin C 40 mg in a specific regimen for induction (q weekly × 6 weeks) and maintenance (q monthly × 12 months). Responses were consistent across groups of BCG therapy (adequate vs BCG-exposed). Physicians were slightly more likely to use a maintenance regimen for the adequate BCG patient.
Conclusions:
The most common treatments received by patients with BCG-unresponsive and BCG-exposed NMIBC were intravesical chemotherapy (single-agent gemcitabine or mitomycin C), regardless of whether CIS or papillary disease was present.
Details
- Title: Subtitle
- US Clinical Practice Patterns of Intravesical Chemotherapy for BCG-Unresponsive and BCG-Exposed Non-muscle Invasive Bladder Cancer
- Creators
- Mohamad Abou Chakra - University of Iowa Hospitals and ClinicsNeal D. Shore - Carolina Urologic Research CenterRachelle Dillon - Research ManitobaMichael A. O'Donnell - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Urology Practice, Vol.11(1), pp.97-107
- DOI
- 10.1097/UPJ.0000000000000481
- PMID
- 37903746
- ISSN
- 2352-0779
- Language
- English
- Electronic publication date
- 10/30/2023
- Date published
- 01/2024
- Academic Unit
- Urology
- Record Identifier
- 9984502956002771
Metrics
9 Record Views